Literature DB >> 14681318

Genetic alterations in goblet cell carcinoids of the vermiform appendix and comparison with gastrointestinal carcinoid tumors.

Mirela Stancu1, Tsung-Teh Wu, Charita Wallace, Patrick S Houlihan, Stanley R Hamilton, Asif Rashid.   

Abstract

Goblet cell carcinoid is a relatively rare neuroendocrine tumor of the vermiform appendix with poorly understood molecular pathogenesis. We studied the clinicopathologic features and genetic alterations, including allelic loss of chromosomes 11q, 16q, and 18q; sequencing of the K-ras, beta-catenin, and DPC4 (SMAD4) genes; and p53 overexpression and loss of DPC4 by immunohistochemistry; in 16 goblet cell carcinoids. We compared the allelic loss in goblet cell carcinoids to those in 18 gastrointestinal carcinoid tumors. For goblet cell carcinoids, appendiceal perforation was the most common (70%, 7/10) clinical presentation. The mean tumor size was 2.0 +/- 1.5 cm (range, 0.4 to 4.5 cm). The tumor invaded to appendiceal serosa in 50% (8/16) of patients, and two patients had metastasis in lymph nodes or adjoining viscera. With mean follow-up of 24 +/- 14 months (median, 23 mo), 1 of 10 patients had died of disease, and 2 others had tumor recurrence. All four patients with metastases, recurrences, and/or death from disease had serosal involvement at presentation (P =.02). Loss of heterozygosity of chromosome 11q was present in 25% of goblet cell carcinoids, 14% of ileal carcinoid tumors, and 9% of nonileal carcinoid tumors; of chromosome 16q in 38%, 29%, and 0 (P =.02); and of chromosome 18q in 56%, 86%, and 9% (P =.002), respectively. No mutations of K-ras, beta-catenin, or DPC4 genes; p53 overexpression; or loss of staining for DPC4 was present in any tumors. These findings suggest that allelic loss of chromosomes 11q, 16q, and 18q in goblet cell carcinoids and ileal carcinoids may have an important role in the pathogenesis of these tumors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14681318     DOI: 10.1097/01.MP.0000097362.10330.B1

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  28 in total

1.  Clinicopathological features and immunoexpression profiles of goblet cell carcinoid and typical carcinoid of the appendix.

Authors:  Yong Jiang; Hu Long; Weiya Wang; Huawei Liu; Yuan Tang; Xiuhui Zhang
Journal:  Pathol Oncol Res       Date:  2010-07-18       Impact factor: 3.201

2.  A subset of high-grade pulmonary neuroendocrine carcinomas shows up-regulation of matrix metalloproteinase-7 associated with nuclear beta-catenin immunoreactivity, independent of EGFR and HER-2 gene amplification or expression.

Authors:  Giuseppe Pelosi; Aldo Scarpa; Giulia Veronesi; Lorenzo Spaggiari; Barbara Del Curto; Patrick S Moore; Patrick Maisonneuve; Angelica Sonzogni; Michele Masullo; Giuseppe Viale
Journal:  Virchows Arch       Date:  2005-09-13       Impact factor: 4.064

3.  Genetic differentiation of appendiceal tumor malignancy: a guide for the perplexed.

Authors:  Irvin M Modlin; Mark Kidd; Igor Latich; Michelle N Zikusoka; Geeta N Eick; Shrikant M Mane; Robert L Camp
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

4.  Goblet cell carcinoid of the rectum with lymph node metastasis: report of a case.

Authors:  Takumi Yamabuki; Makoto Omi; Atsuya Yonemori; Satoshi Hayama; Soichi Murakami; Hitoshi Inomata; Michio Mori; Kazuyoshi Nihei
Journal:  Surg Today       Date:  2011-08-26       Impact factor: 2.549

5.  Expression of beta-catenin in gastroenteropancreatic endocrine tumours: a study of 229 cases.

Authors:  V Hervieu; F Lepinasse; G Gouysse; O Guillaud; C Barel; M-L Chambonniere; P-P Bringuier; G Poncet; C Lombard-Bohas; C Partensky; J-A Chayvialle; J-Y Scoazec
Journal:  J Clin Pathol       Date:  2006-05-26       Impact factor: 3.411

6.  Molecular Characterization of Appendiceal Goblet Cell Carcinoid.

Authors:  Hiroyuki Arai; Yasmine Baca; Francesca Battaglin; Natsuko Kawanishi; Jingyuan Wang; Shivani Soni; Wu Zhang; Joshua Millstein; Curtis Johnston; Richard M Goldberg; Philip A Philip; Andreas Seeber; Joanne Xiu; Jimmy J Hwang; Anthony F Shields; John L Marshall; W Michael Korn; Heinz-Josef Lenz
Journal:  Mol Cancer Ther       Date:  2020-10-09       Impact factor: 6.261

Review 7.  [Gastrointestinal mixed adenoneuroendocrine carcinomas. An attempt at classification of mixed cancers].

Authors:  S Reu; J Neumann; T Kirchner
Journal:  Pathologe       Date:  2012-02       Impact factor: 1.011

8.  Loss of DPC4/SMAD4 expression in primary gastrointestinal neuroendocrine tumors is associated with cancer-related death after resection.

Authors:  Christina L Roland; Lee F Starker; Y Kang; Deyali Chatterjee; Jeannelyn Estrella; Asif Rashid; Matthew H Katz; Thomas A Aloia; Jeffrey E Lee; Arvind Dasari; James C Yao; Jason B Fleming
Journal:  Surgery       Date:  2016-11-03       Impact factor: 3.982

9.  Appendiceal neuroendocrine tumors: Recent insights and clinical implications.

Authors:  John Griniatsos; Othon Michail
Journal:  World J Gastrointest Oncol       Date:  2010-04-15

10.  Role of transforming growth factor-beta1-smad signal transduction pathway in patients with hepatocellular carcinoma.

Authors:  Guo-Zhong Ji; Xue-Hao Wang; Lin Miao; Zheng Liu; Ping Zhang; Fa-Ming Zhang; Jian-Bing Yang
Journal:  World J Gastroenterol       Date:  2006-01-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.